Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: A double-blind, randomised controlled clinical trial of efficacy and safety

Diabetologia

Volumn 55, Issue 4, 2012, Pages 926-935

  Nathanson, D ^a   Ullman, B ^a   Lofstrom U ^a   Hedman, A ^a   Frick, M ^a   Sjoholm A ^a   Nystrom T ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Congestive heart failure; Double blind randomised trial; Exenatide; GLP 1; Heart catheterisation; Type 2 diabetes

Indexed keywords

C PEPTIDE; DIGOXIN; EXENDIN 4; FATTY ACID; GLYCERYL TRINITRATE; PLACEBO;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CHRONOTROPISM; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEART CATHETERIZATION; HEART EJECTION FRACTION; HEART HEMODYNAMICS; HEART INDEX; HEART OUTPUT; HEART RATE; HEART RIGHT ATRIUM PRESSURE; HEART STROKE VOLUME; HUMAN; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MALE; MEAN ARTERIAL PRESSURE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SWEDEN; SYSTEMIC VASCULAR RESISTANCE; SYSTOLIC BLOOD PRESSURE; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE; HEART RATE; HEMODYNAMICS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PEPTIDES; VENOMS;

EID: 84862521094     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-011-2440-x     Document Type: Article

References (37)

1. Nyström T (2008) The potential beneficial role of glucagon-like peptide-1 in endothelial dysfunction and heart failure associated with insulin resistance. Hormon Metab Res 40:593-606
2. Nikolaidis LA, Elahi D, Hentosz T et al (2004) Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 110:955-961
3. Nikolaidis LA, Mankad S, Sokos GG et al (2004) Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109:962-965
4. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP (2006) Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 12:694-699
5. Halbirk M, Norrelund H, Møller N et al (2010) Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. Am J Physiol 298: H1096-H1102
6. Sokos GG, Bolukoglu H, German J et al (2007) Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol 100:824-829
7. Read PA, Hoole SP, White PA et al (2011) A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans. Circ Cardiovasc Interv 4:266-272
8. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M (2008) Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and-independent pathways. Circulation 117:2340-2350
9. Vyas AK, Yang KC, Woo D et al (2011) Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy. PLoS One 6:e17178
10. Liu Q, Anderson C, Broyde A et al (2010) Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. Cardiovasc Diabetol 9:76
11. Edwards CM, Stanley SA, Davis R et al (2001) Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol 281:E155-E161
12. Sonne DP, Engstrøm T, Treiman M (2008) Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept 146:243-249
13. Slawsky MT, Colucci WS, Gottlieb SS et al (2000) Acute hemo-dynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation 102:2222-2227
14. Barragan JM, Rodriguez RE, Eng J, Blazquez E (1996) Interactions of exendin-(9-39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats. Regul Pept 67:63-68
15. Yamamoto H, Lee CE, Marcus JN et al (2002) Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Investig 110:43-52
16. Nyström T, Gutniak MK, Zhang Q et al (2004) Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol 287: E1209-E1215
17. Gros R, You X, Baggio LL et al (2003) Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology 144:2242-2252
18. Griffioen KJ, Wan R, Okun E et al (2010) GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmis-sion to cardiac vagal neurons. Cardiovasc Res 89:72-78
19. Cabou C, Campistron G, Marsollier N et al (2008) Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity. Diabetes 57:2577-2587
20. Bharucha AE, Charkoudian N, Andrews CN et al (2008) Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans. Am J Physiol 295:R874-R880
21. Kothare PA, Linnebjerg H, Isaka Y et al (2008) Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus. J Clin Pharmacol 48:1389-1399
22. Gill A, Hoogwerf BJ, Burger J et al (2010) Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. Cardiovasc Diabetol 9:6
23. Best JH, Hoogwerf BJ, Herman WH et al (2010) Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care 34:90-95
24. van Heerebeek L, Hamdani N, Handoko ML et al (2008) Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 117:43-51
25. Taegtmeyer H (2004) Cardiac metabolism as a target for the treatment of heart failure. Circulation 110:894-896
26. Bhashyam S, Fields AV, Patterson B et al (2010) Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy. Circulation 3:512-521
27. Poornima I, Brown SB, Bhashyam S, Parikh P, Bolukoglu H, Shannon RP (2008) Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. Circulation 1:153-160
28. Crajoinas RO, Oricchio FT, Pessoa TD et al (2011) Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. Am J Physiol Renal Physiol 301:F355-F363
29. Gutzwiller JP, Tschopp S, Bock A et al (2004) Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 89:3055-3061
30. Vila Petroff MG, Egan JM, Wang X, Sollott SJ (2001) Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes. Circ Res 89:445-452
31. Lønborg J, Vejlstrup N, Kelbaek H, et al. (2011) Exenatide reduces reperfusion injury in patients with ST-segment elevation myocar-dial infarction. Eur H J doi:10.1093/eurheartj/ehr309 [Epub ahead of print]
32. Gardiner SM, March JE, Kemp PA, Bennett T (2006) Mesenteric vasoconstriction and hindquarters vasodilatation accompany the pressor actions of exendin-4 in conscious rats. J Pharmacol Exp Ther 316:852-859
33. Erdogdu O, Nathanson D, Sjöholm A, Nyström T, Zhang Q (2010) Exendin-4 stimulates proliferation of human coronary artery endo-thelial cells through eNOS-, PKA-and PI3K/Akt-dependent pathways and requires GLP-1 receptor. Mol Cell Endocrinol 325:26-35
34. Nathanson D, Erdogdu O, Pernow J, Zhang Q, Nyström T (2009) Endothelial dysfunction induced by triglycerides is not restored by exenatide in rat conduit arteries ex vivo. Regul Pept 157:8-13
35. Gardiner SM, March JE, Kemp PA, Bennett T (2008) Autonomic nervous system-dependent and-independent cardiovascular effects of exendin-4 infusion in conscious rats. Br J Pharmacol 154:60-71
36. Opie LH, Knuuti J (2009) The adrenergic-fatty acid load in heart failure. J Am Coll Cardiol 54:1637-1646
37. Peterson LR, Saeed IM, McGill JB et al (2011) Sex and type 2 diabetes: obesity-independent effects on left ventricular substrate metabolism and relaxation in humans. Obesity (Silver Spring). doi:10.1038/oby.2011.208